Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000157)
SBP Name
DART MGD-010
Synonyms
MGD010; PRV-3279; PRV3279
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase II
Protein Scaffold Information of This SBP
Scaffold ID PS028
Scaffold Info
[1]
Scaffold Name DART
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Low affinity immunoglobulin gamma Fc region receptor II-b
BTS Info
Modulator Acute hepatitis A [ICD-11: 1E50.0] N.A. MacroGenics [1]
B-cell antigen receptor complex-associated protein beta chain
BTS Info
Modulator Acute hepatitis A [ICD-11: 1E50.0];Systemic lupus erythematosus [ICD-11: 4A40.0] N.A. MacroGenics [1]
Clinical Trial Information of This SBP
NCT02376036 Click to show the Detail
Indication Healthy
Phase Phase I
Title A Phase I, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of?MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART?) Bi-specific Antibody-Based Molecule, in Healthy Subjects
Status Completed
Sponsor MacroGenics
NCT03955666 Click to show the Detail
Indication Safety
Phase Phase I
Title A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects (PREVAIL1)
Status Completed
Sponsor Provention Bio, Inc.
NCT05087628 Click to show the Detail
Indication Systemic Lupus Erythematosus
Phase Phase II
Title PRV-3279-2a Trial in Systemic Lupus
Status Active, not recruiting
Sponsor Provention Bio, a Sanofi Company
References
1 MacroGenics. MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017). Jun 17 2017.